Other Event

Other Event

Other Adverse Events are non-serious adverse events that exceed a specific frequency threshold (typically 5% within any study arm). These events are reported to provide comprehensive safety information about all noteworthy adverse occurrences during clinical trials. Each other event is categorized by term, organ system, assessment type, and source vocabulary for standardized reporting.

Other Event path is as follows:

Study -> Results Section -> Adverse Events Module -> Other Event

Study -> Results Section -> Adverse Events Module -> Other Event -> Other Event Stats

Other Event


Ignite Creation Date: 2025-12-25 @ 1:40 AM
Ignite Modification Date: 2025-12-25 @ 11:56 PM
NCT ID: NCT02367794
Term: DRY SKIN
Organ System: Skin and subcutaneous tissue disorders
Assessment Type: SYSTEMATIC_ASSESSMENT
Source Vocabulary: MeDRA Version 23.1
Notes: None
Study: NCT02367794
Study Brief: A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131]
Other Event Stats (If Any):

Other Event Stats

Group ID # Events # Affected # At Risk View
EG000 5 5 334 View
EG001 21 19 334 View
EG002 14 13 332 View